Join
Live feed
·
PRReleasevia Quantisnow
Tiziana Life Sciences Ltd. logo

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

ByQuantisnow·Wall Street's wire, on your screen.
TLSA· Tiziana Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TLSA (Tiziana Life Sciences Ltd.) and more on Quantisnow.